<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:15:14Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8892042" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8892042</identifier>
        <datestamp>2022-03-04</datestamp>
        <setSpec>europace</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Europace</journal-id>
              <journal-id journal-id-type="iso-abbrev">Europace</journal-id>
              <journal-id journal-id-type="publisher-id">europace</journal-id>
              <journal-title-group>
                <journal-title>Europace</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1099-5129</issn>
              <issn pub-type="epub">1532-2092</issn>
              <publisher>
                <publisher-name>Oxford University Press</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8892042</article-id>
              <article-id pub-id-type="pmcid">PMC8892042</article-id>
              <article-id pub-id-type="pmc-uid">8892042</article-id>
              <article-id pub-id-type="pmid">34426836</article-id>
              <article-id pub-id-type="pmid">34426836</article-id>
              <article-id pub-id-type="doi">10.1093/europace/euab186</article-id>
              <article-id pub-id-type="publisher-id">euab186</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Clinical Research</subject>
                  <subj-group subj-group-type="category-toc-heading">
                    <subject>Atrial Fibrillation</subject>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="category-taxonomy-collection">
                  <subject>AcademicSubjects/MED00200</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Characteristics of patients with atrial high rate episodes detected by implanted defibrillator and resynchronization devices</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Miyazawa</surname>
                    <given-names>Kazuo</given-names>
                  </name>
                  <xref rid="euab186-aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6357-5213</contrib-id>
                  <name>
                    <surname>Pastori</surname>
                    <given-names>Daniele</given-names>
                  </name>
                  <xref rid="euab186-aff2" ref-type="aff">2</xref>
                  <xref rid="euab186-aff3" ref-type="aff">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Martin</surname>
                    <given-names>David T</given-names>
                  </name>
                  <xref rid="euab186-aff4" ref-type="aff">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Choucair</surname>
                    <given-names>Wassim K</given-names>
                  </name>
                  <xref rid="euab186-aff5" ref-type="aff">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Halperin</surname>
                    <given-names>Jonathan L</given-names>
                  </name>
                  <xref rid="euab186-aff6" ref-type="aff">6</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Lip</surname>
                    <given-names>Gregory Y H</given-names>
                  </name>
                  <xref rid="euab186-cor1" ref-type="corresp"/>
                  <xref rid="euab186-aff3" ref-type="aff">3</xref>
                  <xref rid="euab186-aff7" ref-type="aff">7</xref>
                  <!--gregory.lip@liverpool.ac.uk-->
                </contrib>
                <contrib contrib-type="author">
                  <collab>the IMPACT Study Investigators</collab>
                </contrib>
              </contrib-group>
              <aff id="euab186-aff1"><label>1</label><institution>Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine</institution>, 1-8-1 Inohana Chuo-ku, Chiba 260-8677, <country country="JP">Japan</country></aff>
              <aff id="euab186-aff2"><label>2</label><institution>Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome</institution>, Piazzale Aldo Moro, Rome 5 00185, <country country="IT">Italy</country></aff>
              <aff id="euab186-aff3"><label>3</label><institution>Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart &amp; Chest Hospital</institution>, Thomas Drive, Liverpool L14 3PE, <country country="GB">UK</country></aff>
              <aff id="euab186-aff4"><label>4</label><institution>Department of Medicine, Brigham and Women’s Hospital</institution>, Boston, 41 Mall Road Burlington, MA 01805, <country country="US">USA</country></aff>
              <aff id="euab186-aff5"><label>5</label><institution>Heart and Rhythm Institute of South Texas</institution>, 8122 Datapoint Dr, San Antonio, TX 78229, <country country="US">USA</country></aff>
              <aff id="euab186-aff6"><label>6</label><institution>Department of Cardiovascular Diseases, Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, Mount Sinai Heart</institution>, 1 Gustave L. Levy Pl, New York, NY 10029, <country country="US">USA</country></aff>
              <aff id="euab186-aff7"><label>7</label><institution>Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University</institution>, Fredrik Bajers Vej 7K, Aalborg Øst 9220, <country country="DK">Denmark</country></aff>
              <author-notes>
                <corresp id="euab186-cor1">Corresponding author. Tel: +44 121 507 5080; fax: +44 121 507 5503. <italic toggle="yes">E-mail address</italic>: <email>gregory.lip@liverpool.ac.uk</email></corresp>
              </author-notes>
              <pub-date pub-type="collection">
                <month>3</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="epub" iso-8601-date="2021-08-24">
                <day>24</day>
                <month>8</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>24</day>
                <month>8</month>
                <year>2021</year>
              </pub-date>
              <volume>24</volume>
              <issue>3</issue>
              <fpage>375</fpage>
              <lpage>383</lpage>
              <history>
                <date date-type="received">
                  <day>17</day>
                  <month>3</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>05</day>
                  <month>7</month>
                  <year>2021</year>
                </date>
                <date date-type="editorial-decision">
                  <day>24</day>
                  <month>6</month>
                  <year>2021</year>
                </date>
                <date date-type="corrected-typeset">
                  <day>24</day>
                  <month>8</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology</copyright-statement>
                <copyright-year>2021</copyright-year>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
              </permissions>
              <self-uri xlink:href="euab186.pdf"/>
              <related-article related-article-type="companion" ext-link-type="doi" id="RA1" xlink:href="10.1093/europace/euab242"/>
              <abstract>
                <title>Abstract</title>
                <sec id="s1">
                  <title>Aims</title>
                  <p>Atrial high rate episodes (AHREs) are associated with increased risks of thromboembolism and cardiovascular mortality. However, the clinical characteristics of patients developing AHRE of various durations are not well studied.</p>
                </sec>
                <sec id="s2">
                  <title>Methods and results</title>
                  <p>This was an ancillary analysis of the multicentre, randomized IMPACT trial. In the present analysis, we classified patients according to the duration of AHRE ≤6 min, &gt;6 min to ≤6 h, &gt;6 to ≤24 h and &gt;24 h, and investigated the association between clinical factors and the development of each duration of AHRE. Of 2718 patients included in the trial, 945 (34.8%) developed AHRE. The incidence rates of each AHRE duration category were 5.4/100, 12.0/100, 6.8/100, and 3.3/100 patient-years, respectively. The incidence rates of AHRE &gt;6 h were significantly higher in patients at high risk of thromboembolism (CHADS<sub>2</sub> score ≥3) compared to those at low risk (CHADS<sub>2</sub> score 1 or 2). Using Cox regression analysis, age ≥65 years and history of atrial fibrillation (AF) and/or atrial flutter (AFL) were risk factors for AHRE &gt;6 min. In addition, hypertension was associated with AHRE &gt;24 h (hazard ratio 2.13, 95% confidence interval 1.24–3.65, <italic toggle="yes">P </italic>=<italic toggle="yes"> </italic>0.006).</p>
                </sec>
                <sec id="s3">
                  <title>Conclusion</title>
                  <p>Atrial high rate episode &gt;6 min to ≤6 h were most prevalent among all AHRE duration categories. Longer AHREs were more common in patients at risk of thromboembolism. Age and history of AF/AFL were risk factors for AHRE &gt;6 min. Furthermore, hypertension showed a strong impact on the development of AHRE &gt;24 h rather than age.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd>Atrial fibrillation</kwd>
                <kwd>Atrial high rate episode</kwd>
                <kwd>Stroke</kwd>
                <kwd>Thromboembolism</kwd>
                <kwd>Clinical profile</kwd>
                <kwd>Cardiac implantable electronic device</kwd>
              </kwd-group>
              <funding-group>
                <award-group award-type="grant">
                  <funding-source>
                    <institution-wrap>
                      <institution>IMPACT Study was supported by BIOTRONIK, Inc</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
              <counts>
                <page-count count="9"/>
              </counts>
            </article-meta>
          </front>
          <body>
            <p>
              <boxed-text id="euab186-BOX1" position="float">
                <label>What’s new?</label>
                <list list-type="bullet">
                  <list-item>
                    <p>Atrial high rate episode (AHRE) lasting &gt;6 min to ≤6 h most frequently occurred among duration-categorized AHREs in patients at risk of life-threatening arrhythmias.</p>
                  </list-item>
                  <list-item>
                    <p>Atrial high rate episodes lasting &gt;6 h more frequently occurred in patients at high risk of thromboembolism compared to those at low risk.</p>
                  </list-item>
                  <list-item>
                    <p>Age and history of atrial fibrillation or flutter were risk factors associated with the development of AHREs lasting &gt;6 min.</p>
                  </list-item>
                  <list-item>
                    <p>Hypertension was a risk factor for the development of long AHRE (&gt;24 h), with a greater impact than age.</p>
                  </list-item>
                </list>
              </boxed-text>
            </p>
            <sec sec-type="intro">
              <title>Introduction</title>
              <p>Atrial fibrillation (AF) is associated with increased risks of stroke, myocardial infarction, heart failure, and mortality.<xref rid="euab186-B1" ref-type="bibr"><sup>1</sup></xref> A substantial proportion of AF is asymptomatic and often eludes detection by conventional diagnostic methods such as physical examination, 12-lead electrocardiogram (ECG), and 24-h Holter ECG.<xref rid="euab186-B2" ref-type="bibr"><sup>2</sup></xref> In approximately one-quarter of patients with stroke, no overt aetiology is identified, and these events may be related to atrial high rate episodes (AHREs), which generally represent either subclinical AF or atrial flutter (AFL).<xref rid="euab186-B3" ref-type="bibr"><sup>3</sup></xref></p>
              <p>Cardiac implantable electronic devices (CIEDs) can automatically record all spontaneous episodes of atrial and ventricular arrhythmias regardless of symptoms. Previous studies demonstrated that AHRE is associated with increased risks of developing clinically manifest AF,<xref rid="euab186-B4" ref-type="bibr"><sup>4</sup></xref> thromboembolism,<xref rid="euab186-B5" ref-type="bibr"><sup>5</sup></xref><sup>,</sup><xref rid="euab186-B7" ref-type="bibr"><sup>7</sup></xref> cardiovascular events,<xref rid="euab186-B8" ref-type="bibr"><sup>8</sup></xref> and mortality.<xref rid="euab186-B9" ref-type="bibr"><sup>9</sup></xref> Atrial high rate episode lasting more than 5 or 6 min is considered clinically relevant, and patients presenting with AHRE should be assessed for other stroke risk factors.<xref rid="euab186-B5" ref-type="bibr"><sup>5,</sup></xref><xref rid="euab186-B9" ref-type="bibr"><sup>9</sup></xref> Thus, current clinical practice guidelines address diagnosis and management of patients with AHRE.<xref rid="euab186-B10" ref-type="bibr"><sup>10</sup></xref> Although inflammation at the time of CIED implantation is associated with subsequently detected AHRE,<xref rid="euab186-B11" ref-type="bibr"><sup>11</sup></xref> the clinical profiles of patients with AHRE of various durations have not been defined.</p>
              <p>The IMPACT trial included 2718 patients with implantable cardioverter-defibrillators (ICDs) or cardiac resynchronization therapy (CRT) devices, and examined the strategy of basing anticoagulation therapy on the burden of AHRE and each patient’s intrinsic risk of thrombeoembolism.<xref rid="euab186-B13" ref-type="bibr"><sup>13</sup></xref> In a sub-study of the trial, we sought to identify clinical characteristics of patients with various burdens of AHRE and to assess the risk factors associated with the development of AHRE of various durations in patients with ICD or CRT-D devices.</p>
            </sec>
            <sec sec-type="methods">
              <title>Methods</title>
              <sec>
                <title>Study population</title>
                <p>The study design of IMPACT (ClinicalTrials.gov identifier NCT00559988) has been previously described.<xref rid="euab186-B12" ref-type="bibr"><sup>12</sup></xref> In brief, this interventional, single-blinded, randomized, multicentre trial enrolled 2718 patients with dual-chamber ICD or CRT-D devices (Biotronik, Inc.) at 104 centres in North America, Europe, and Australia. Eligible patients had at least one additional stroke risk factor (CHADS<sub>2</sub> score ≥1) and were deemed able to tolerate anticoagulation. Patients with permanent AF or contraindications to anticoagulation were excluded. Patients were randomized to a strategy of starting and stopping anticoagulation based on remote rhythm monitoring vs. usual office-based follow-up with anticoagulation based on standard clinical criteria. The protocol was approved by institutional review boards governing human research.</p>
              </sec>
              <sec>
                <title>Definition of atrial high rate episode</title>
                <p>Atrial high rate episode was defined as atrial tachyarrhythmias with ≥36 of 48 atrial beats and cycle lengths ≤300 ms (atrial rates ≥200 b.p.m.). For this analysis, we subdivided AHRE into five categories according to duration as no AHRE, episodes ≤6 min, &gt;6 min but ≤6 h, &gt;6 h but ≤24 h, and those lasting &gt;24 h. Classification was based on the longest AHRE during follow-up (median 701 days and cumulative 5430 patient-years).</p>
              </sec>
              <sec>
                <title>Statistical analysis</title>
                <p>Continuous variables were expressed as mean ± standard deviation, and categorical variables as numbers and percentages. We compared categorical variables using the <italic toggle="yes">χ</italic><sup>2</sup> test and continuous variables using the independent samples <italic toggle="yes">t</italic>-test for normally distributed data or Mann–Whitney <italic toggle="yes">U</italic> test for non-normal distribution. Significance was accepted at the 95% confidence interval (CI, two-sided <italic toggle="yes">P</italic> ≤ 0.05). Since we performed multiple (four pairwise) comparisons of baseline characteristics, the Bonferroni correction was applied to adjust the threshold for significance (0.05/4 = 0.0125).</p>
                <p>To identify independent risk factors associated with AHRE, we performed Cox proportional hazards regression analysis. The multivariable models were adjusted for underlying heart disease, medications, and components of the CHA<sub>2</sub>DS<sub>2</sub>-VASc score as covariates. The cumulative incidence of AHRE of various durations was displayed using the Kaplan–Meier method. Receiver operating characteristic (ROC) analysis was performed to evaluate the discrimination of the risk scores to predict the development of AHRE based on the area under the ROC curves (AUC). To compare the predictive models, we calculated the difference between the AUCs by the method of DeLong <italic toggle="yes">et al</italic>.<xref rid="euab186-B13" ref-type="bibr"><sup>13</sup></xref></p>
                <p>Statistical analyses were performed using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA), SPSS version 21 (IBM Corp., Armonk, NY, USA), and StatXact version 10 (Cytel, Cambridge, MA, USA).</p>
              </sec>
            </sec>
            <sec sec-type="results">
              <title>Results</title>
              <sec>
                <title>Baseline patient characteristics</title>
                <p>Baseline characteristics of enrolled patients are shown in <italic toggle="yes">Table <xref rid="euab186-T1" ref-type="table">1</xref></italic>. Mean age was 64.4 years; 26.3% were women. Of all patients, 64% had ICD and 36% CRT-D devices. During a mean follow-up of 2.0 ± 1.2 years, 945 patients (34.8%) developed AHRE; 292 (10.7%) had AHRE ≤6 min, 284 (10.4%) &gt;6 min to ≤6 h, 187 (6.9%) &gt;6 to ≤24 h, and 182 (6.7%) &gt;24 h.</p>
                <table-wrap position="float" id="euab186-T1">
                  <label>Table 1</label>
                  <caption>
                    <p> Baseline characteristics of patients</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col valign="top" align="left" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="char" char="." span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="char" char="." span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="char" char="." span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="char" char="." span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th rowspan="2" colspan="1"/>
                        <th rowspan="2" colspan="1">No AHRE group (<italic toggle="yes">n</italic> = 1773)</th>
                        <th colspan="8" rowspan="1">AHREs groups<hr/></th>
                      </tr>
                      <tr>
                        <th rowspan="1" colspan="1">≤6 min (<italic toggle="yes">n</italic> = 292)</th>
                        <th rowspan="1" colspan="1"><italic toggle="yes">P</italic>-value</th>
                        <th rowspan="1" colspan="1">&gt;6 min/≤6 h (<italic toggle="yes">n</italic> = 284)</th>
                        <th rowspan="1" colspan="1"><italic toggle="yes">P</italic>-value<sup>a</sup></th>
                        <th rowspan="1" colspan="1">&gt;6 h/≤24 h (<italic toggle="yes">n</italic> = 187)</th>
                        <th rowspan="1" colspan="1"><italic toggle="yes">P</italic>-value<sup>a</sup></th>
                        <th rowspan="1" colspan="1">&gt;24 h (<italic toggle="yes">n</italic> = 182)</th>
                        <th rowspan="1" colspan="1"><italic toggle="yes">P</italic>-value<sup>a</sup></th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td rowspan="1" colspan="1">Age (years)</td>
                        <td rowspan="1" colspan="1">63.9 ± 11.2</td>
                        <td rowspan="1" colspan="1">62.4 ± 11.1</td>
                        <td rowspan="1" colspan="1">0.050</td>
                        <td rowspan="1" colspan="1">66.8 ± 10.6</td>
                        <td rowspan="1" colspan="1">&lt;0.001</td>
                        <td rowspan="1" colspan="1">66.8 ± 10.6</td>
                        <td rowspan="1" colspan="1">&lt;0.001</td>
                        <td rowspan="1" colspan="1">66.5 ± 10.6</td>
                        <td rowspan="1" colspan="1">0.001</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Women</td>
                        <td rowspan="1" colspan="1">490 (27.6)</td>
                        <td rowspan="1" colspan="1">86 (29.5)</td>
                        <td rowspan="1" colspan="1">0.522</td>
                        <td rowspan="1" colspan="1">61 (21.5)</td>
                        <td rowspan="1" colspan="1">0.030</td>
                        <td rowspan="1" colspan="1">38 (20.3)</td>
                        <td rowspan="1" colspan="1">0.032</td>
                        <td rowspan="1" colspan="1">40 (22.0)</td>
                        <td rowspan="1" colspan="1">0.102</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Hypertension</td>
                        <td rowspan="1" colspan="1">1480 (83.5)</td>
                        <td rowspan="1" colspan="1">243 (83.2)</td>
                        <td rowspan="1" colspan="1">0.914</td>
                        <td rowspan="1" colspan="1">227 (79.9)</td>
                        <td rowspan="1" colspan="1">0.140</td>
                        <td rowspan="1" colspan="1">160 (85.6)</td>
                        <td rowspan="1" colspan="1">0.463</td>
                        <td rowspan="1" colspan="1">167 (91.8)</td>
                        <td rowspan="1" colspan="1">0.003</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Diabetes mellitus</td>
                        <td rowspan="1" colspan="1">733 (41.3)</td>
                        <td rowspan="1" colspan="1">111 (38.0)</td>
                        <td rowspan="1" colspan="1">0.284</td>
                        <td rowspan="1" colspan="1">107 (37.7)</td>
                        <td rowspan="1" colspan="1">0.243</td>
                        <td rowspan="1" colspan="1">74 (39.6)</td>
                        <td rowspan="1" colspan="1">0.243</td>
                        <td rowspan="1" colspan="1">84 (46.2)</td>
                        <td rowspan="1" colspan="1">0.210</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Heart failure</td>
                        <td rowspan="1" colspan="1">1607 (90.6)</td>
                        <td rowspan="1" colspan="1">252 (86.3)</td>
                        <td rowspan="1" colspan="1">0.022</td>
                        <td rowspan="1" colspan="1">257 (90.5)</td>
                        <td rowspan="1" colspan="1">0.938</td>
                        <td rowspan="1" colspan="1">164 (87.7)</td>
                        <td rowspan="1" colspan="1">0.938</td>
                        <td rowspan="1" colspan="1">165 (90.7)</td>
                        <td rowspan="1" colspan="1">0.992</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">History of stroke/TIA</td>
                        <td rowspan="1" colspan="1">159 (9.0)</td>
                        <td rowspan="1" colspan="1">34 (11.6)</td>
                        <td rowspan="1" colspan="1">0.146</td>
                        <td rowspan="1" colspan="1">23 (8.1)</td>
                        <td rowspan="1" colspan="1">0.632</td>
                        <td rowspan="1" colspan="1">14 (7.5)</td>
                        <td rowspan="1" colspan="1">0.632</td>
                        <td rowspan="1" colspan="1">13 (7.1)</td>
                        <td rowspan="1" colspan="1">0.408</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Vascular disease</td>
                        <td rowspan="1" colspan="1">1035 (58.4)</td>
                        <td rowspan="1" colspan="1">157 (53.7)</td>
                        <td rowspan="1" colspan="1">0.140</td>
                        <td rowspan="1" colspan="1">165 (58.1)</td>
                        <td rowspan="1" colspan="1">0.930</td>
                        <td rowspan="1" colspan="1">115 (61.5)</td>
                        <td rowspan="1" colspan="1">0.930</td>
                        <td rowspan="1" colspan="1">112 (61.5)</td>
                        <td rowspan="1" colspan="1">0.409</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Non-ischaemic CM</td>
                        <td rowspan="1" colspan="1">617 (34.8)</td>
                        <td rowspan="1" colspan="1">119 (40.8)</td>
                        <td rowspan="1" colspan="1">0.049</td>
                        <td rowspan="1" colspan="1">106 (37.3)</td>
                        <td rowspan="1" colspan="1">0.408</td>
                        <td rowspan="1" colspan="1">65 (34.8)</td>
                        <td rowspan="1" colspan="1">0.991</td>
                        <td rowspan="1" colspan="1">55 (30.2)</td>
                        <td rowspan="1" colspan="1">0.215</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Valvular disease</td>
                        <td rowspan="1" colspan="1">899 (50.7)</td>
                        <td rowspan="1" colspan="1">160 (54.8)</td>
                        <td rowspan="1" colspan="1">0.198</td>
                        <td rowspan="1" colspan="1">158 (55.6)</td>
                        <td rowspan="1" colspan="1">0.125</td>
                        <td rowspan="1" colspan="1">101 (54.0)</td>
                        <td rowspan="1" colspan="1">0.394</td>
                        <td rowspan="1" colspan="1">106 (58.2)</td>
                        <td rowspan="1" colspan="1">0.054</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">History of AF/AFL</td>
                        <td rowspan="1" colspan="1">138 (7.8)</td>
                        <td rowspan="1" colspan="1">29 (9.9)</td>
                        <td rowspan="1" colspan="1">0.212</td>
                        <td rowspan="1" colspan="1">52 (18.3)</td>
                        <td rowspan="1" colspan="1">&lt;0.001</td>
                        <td rowspan="1" colspan="1">48 (25.7)</td>
                        <td rowspan="1" colspan="1">&lt;0.001</td>
                        <td rowspan="1" colspan="1">63 (34.6)</td>
                        <td rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">CHADS<sub>2</sub> score</td>
                        <td rowspan="1" colspan="1">2.5 ± 1.0</td>
                        <td rowspan="1" colspan="1">2.5 ± 1.1</td>
                        <td rowspan="1" colspan="1">0.341</td>
                        <td rowspan="1" colspan="1">2.5 ± 1.1</td>
                        <td rowspan="1" colspan="1">0.353</td>
                        <td rowspan="1" colspan="1">2.5 ± 1.1</td>
                        <td rowspan="1" colspan="1">0.917</td>
                        <td rowspan="1" colspan="1">2.6 ± 1.0</td>
                        <td rowspan="1" colspan="1">0.074</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">CHA<sub>2</sub>DS<sub>2</sub>-VASc score</td>
                        <td rowspan="1" colspan="1">3.9 ± 1.5</td>
                        <td rowspan="1" colspan="1">3.7 ± 1.4</td>
                        <td rowspan="1" colspan="1">0.070</td>
                        <td rowspan="1" colspan="1">3.9 ± 1.6</td>
                        <td rowspan="1" colspan="1">0.934</td>
                        <td rowspan="1" colspan="1">3.9 ± 1.5</td>
                        <td rowspan="1" colspan="1">0.492</td>
                        <td rowspan="1" colspan="1">4.1 ± 1.4</td>
                        <td rowspan="1" colspan="1">0.055</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">ICD</td>
                        <td rowspan="1" colspan="1">1095 (61.8)</td>
                        <td rowspan="1" colspan="1">211 (72.3)</td>
                        <td rowspan="1" colspan="1">0.001</td>
                        <td rowspan="1" colspan="1">186 (65.5)</td>
                        <td rowspan="1" colspan="1">0.228</td>
                        <td rowspan="1" colspan="1">128 (68.5)</td>
                        <td rowspan="1" colspan="1">0.073</td>
                        <td rowspan="1" colspan="1">112 (61.5)</td>
                        <td rowspan="1" colspan="1">0.953</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Primary prevention of SCD</td>
                        <td rowspan="1" colspan="1">1566 (88.3)</td>
                        <td rowspan="1" colspan="1">247 (84.6)</td>
                        <td rowspan="1" colspan="1">0.071</td>
                        <td rowspan="1" colspan="1">250 (88.0)</td>
                        <td rowspan="1" colspan="1">0.885</td>
                        <td rowspan="1" colspan="1">164 (87.7)</td>
                        <td rowspan="1" colspan="1">0.801</td>
                        <td rowspan="1" colspan="1">164 (90.1)</td>
                        <td rowspan="1" colspan="1">0.474</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Beta-blockers</td>
                        <td rowspan="1" colspan="1">1628 (91.8)</td>
                        <td rowspan="1" colspan="1">267 (91.4)</td>
                        <td rowspan="1" colspan="1">0.825</td>
                        <td rowspan="1" colspan="1">254 (89.4)</td>
                        <td rowspan="1" colspan="1">0.181</td>
                        <td rowspan="1" colspan="1">165 (88.2)</td>
                        <td rowspan="1" colspan="1">0.095</td>
                        <td rowspan="1" colspan="1">165 (90.7)</td>
                        <td rowspan="1" colspan="1">0.588</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">ACE-I/ARB</td>
                        <td rowspan="1" colspan="1">1467 (82.7)</td>
                        <td rowspan="1" colspan="1">253 (86.6)</td>
                        <td rowspan="1" colspan="1">0.098</td>
                        <td rowspan="1" colspan="1">239 (84.2)</td>
                        <td rowspan="1" colspan="1">0.557</td>
                        <td rowspan="1" colspan="1">162 (86.6)</td>
                        <td rowspan="1" colspan="1">0.177</td>
                        <td rowspan="1" colspan="1">155 (85.2)</td>
                        <td rowspan="1" colspan="1">0.408</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Digoxin</td>
                        <td rowspan="1" colspan="1">230 (13.0)</td>
                        <td rowspan="1" colspan="1">39 (13.4)</td>
                        <td rowspan="1" colspan="1">0.857</td>
                        <td rowspan="1" colspan="1">47 (16.6)</td>
                        <td rowspan="1" colspan="1">0.101</td>
                        <td rowspan="1" colspan="1">29 (15.5)</td>
                        <td rowspan="1" colspan="1">0.330</td>
                        <td rowspan="1" colspan="1">34 (18.7)</td>
                        <td rowspan="1" colspan="1">0.032</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">AAD</td>
                        <td rowspan="1" colspan="1">188 (10.6)</td>
                        <td rowspan="1" colspan="1">25 (8.6)</td>
                        <td rowspan="1" colspan="1">0.288</td>
                        <td rowspan="1" colspan="1">30 (10.6)</td>
                        <td rowspan="1" colspan="1">0.984</td>
                        <td rowspan="1" colspan="1">19 (10.2)</td>
                        <td rowspan="1" colspan="1">0.175</td>
                        <td rowspan="1" colspan="1">26 (14.3)</td>
                        <td rowspan="1" colspan="1">0.130</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Statin</td>
                        <td rowspan="1" colspan="1">1310 (73.9)</td>
                        <td rowspan="1" colspan="1">200 (68.5)</td>
                        <td rowspan="1" colspan="1">0.054</td>
                        <td rowspan="1" colspan="1">205 (72.2)</td>
                        <td rowspan="1" colspan="1">0.545</td>
                        <td rowspan="1" colspan="1">144 (77.0)</td>
                        <td rowspan="1" colspan="1">0.355</td>
                        <td rowspan="1" colspan="1">140 (76.9)</td>
                        <td rowspan="1" colspan="1">0.373</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Follow-up periods (days)<sup>b</sup></td>
                        <td rowspan="1" colspan="1">NA</td>
                        <td rowspan="1" colspan="1">827.7 ± 426.9</td>
                        <td rowspan="1" colspan="1">Ref</td>
                        <td rowspan="1" colspan="1">830.4 ± 441.0</td>
                        <td rowspan="1" colspan="1">0.926</td>
                        <td rowspan="1" colspan="1">907.1 ± 443.7</td>
                        <td rowspan="1" colspan="1">0.053</td>
                        <td rowspan="1" colspan="1">936.9 ± 436.2</td>
                        <td rowspan="1" colspan="1">0.008</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="tblfn1">
                      <p>AAD, antiarrhythmic drugs; ACE-I, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; AFL, atrial flutter; AHRE, atrial high rate episode; ARB, angiotensin II receptor blocker; CM, cardiomyopathy; ICD, implantable cardioverter-defibrillator; NA, not applicable; SCD, sudden cardiac death; TIA, transient ischaemic attack.</p>
                    </fn>
                    <fn id="tblfn2">
                      <label>a</label>
                      <p>Versus no AHRE group.</p>
                    </fn>
                    <fn id="tblfn3">
                      <label>b</label>
                      <p>Versus AHRE ≤6 min.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>Patients developing AHRE for ≤6 min were slightly younger, with less heart failure but a higher prevalence of non-ischaemic cardiomyopathy and higher proportion of ICD devices (<italic toggle="yes">Table <xref rid="euab186-T1" ref-type="table">1</xref></italic>). Patients with AHRE lasting &gt;6 min to ≤6 h and &gt;6 to ≤24 h were older and less frequently women than patients without AHRE. Conversely, a history of AF or AFL was more frequent in these groups. Patients with AHRE &gt;24 h were older than those without AHRE but a similar proportion were women. In this group, there was a higher prevalence of AF or AFL at baseline and more frequent use of digoxin (<italic toggle="yes">Table <xref rid="euab186-T1" ref-type="table">1</xref></italic>).</p>
                <p>Of those who developed AHRE, 64.6% had CHADS<sub>2</sub> scores of 2 and 26.2% had CHA<sub>2</sub>DS<sub>2</sub>-VASc scores of 4 (<italic toggle="yes">Figure <xref rid="euab186-F1" ref-type="fig">1</xref></italic>).</p>
                <fig position="float" id="euab186-F1">
                  <label>Figure 1</label>
                  <caption>
                    <p>The distribution of patients with CIED according to the risk scores [(<italic toggle="yes">A</italic>) CHADS<sub>2</sub> score and (<italic toggle="yes">B</italic>) CHA<sub>2</sub>DS<sub>2</sub>-VASc score]. AHRE, atrial high rate episode.</p>
                  </caption>
                  <graphic xlink:href="euab186f1" position="float"/>
                </fig>
              </sec>
              <sec>
                <title>Incidence rates of atrial high rate episode</title>
                <p>The Kaplan–Meier estimates of the cumulative incidence of each AHRE duration are depicted in <italic toggle="yes">Figure <xref rid="euab186-F2" ref-type="fig">2</xref></italic>. The incidence rates of each AHRE category during follow-up were 5.4/100, 12.0/100, 6.8/100, and 3.3/100 patient-years, respectively (<italic toggle="yes">Table <xref rid="euab186-T2" ref-type="table">2</xref></italic>). Time frame over which AHREs were documented was described in <xref rid="sup1" ref-type="supplementary-material">Supplementary material</xref> online, <italic toggle="yes">Table</italic> <italic toggle="yes">S1</italic>. To assess the relationship between incidence rate and thromboembolic risk, we divided patients into two groups according to CHADS<sub>2</sub> score—those at low risk (CHADS<sub>2</sub> score 1 or 2) and those at high risk (CHADS<sub>2</sub> score ≥3)—and compared the incidence rates of each AHRE category in these two groups (<italic toggle="yes">Table <xref rid="euab186-T2" ref-type="table">2</xref></italic>). There were no significant differences between low-risk and high-risk patients in the incidence rates of AHRE ≤6 min and &gt;6 min to ≤6 h [risk ratio (RR) 0.906, 95% CI 0.728–1.128, RR 1.108, 95% CI 0.969–1.266], while the incidence rates of AHRE &gt;6 to ≤24 h, and those lasting &gt;24 h were higher in high-risk patients compared to those with low-risk CHADS<sub>2</sub> scores (RR 1.244, 95% CI 1.029–1.504 and RR 1.476, 95% CI 1.113–1.957, respectively).</p>
                <fig position="float" id="euab186-F2">
                  <label>Figure 2</label>
                  <caption>
                    <p>The cumulative incidence of different burden of AHRE using the Kaplan–Meier method. AHRE, atrial high rate episode.</p>
                  </caption>
                  <graphic xlink:href="euab186f2" position="float"/>
                </fig>
                <table-wrap position="float" id="euab186-T2">
                  <label>Table 2</label>
                  <caption>
                    <p> Incidence rate of each burden of AHREs</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col valign="top" align="left" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="center" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th rowspan="2" colspan="1"/>
                        <th colspan="2" rowspan="1">Overall<hr/></th>
                        <th colspan="2" rowspan="1">Low-risk group (CHADS<sub>2</sub> = 1 or 2)<hr/></th>
                        <th colspan="2" rowspan="1">High-risk group (CHADS<sub>2</sub> ≥ 3)<hr/></th>
                        <th rowspan="2" colspan="1">RR (95% CI)<sup>a</sup></th>
                      </tr>
                      <tr>
                        <th rowspan="1" colspan="1">Number of patients</th>
                        <th rowspan="1" colspan="1">Incidence rate (100 patient-years)</th>
                        <th rowspan="1" colspan="1">Number of patients</th>
                        <th rowspan="1" colspan="1">Incidence rate (100 patient-years)</th>
                        <th rowspan="1" colspan="1">Number of patients</th>
                        <th rowspan="1" colspan="1">Incidence rate (100 patient-years)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td rowspan="1" colspan="1">AHRE ≤ 6 min</td>
                        <td rowspan="1" colspan="1">292</td>
                        <td rowspan="1" colspan="1">5.364</td>
                        <td rowspan="1" colspan="1">167</td>
                        <td rowspan="1" colspan="1">5.60</td>
                        <td rowspan="1" colspan="1">125</td>
                        <td rowspan="1" colspan="1">5.076</td>
                        <td rowspan="1" colspan="1">
                          <p>0.906 (0.73–1.13)</p>
                        </td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">6 min &lt; AHRE ≤ 6 h</td>
                        <td rowspan="1" colspan="1">653</td>
                        <td rowspan="1" colspan="1">11.995</td>
                        <td rowspan="1" colspan="1">341</td>
                        <td rowspan="1" colspan="1">11.439</td>
                        <td rowspan="1" colspan="1">312</td>
                        <td rowspan="1" colspan="1">12.669</td>
                        <td rowspan="1" colspan="1">
                          <p>1.11 (0.97–1.27)</p>
                        </td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">6 h &lt; AHRE ≤ 24 h</td>
                        <td rowspan="1" colspan="1">369</td>
                        <td rowspan="1" colspan="1">6.778</td>
                        <td rowspan="1" colspan="1">182</td>
                        <td rowspan="1" colspan="1">6.105</td>
                        <td rowspan="1" colspan="1">187</td>
                        <td rowspan="1" colspan="1">7.593</td>
                        <td rowspan="1" colspan="1">
                          <p>1.24 (1.03–1.50)</p>
                        </td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">AHRE &gt; 24 h</td>
                        <td rowspan="1" colspan="1">182</td>
                        <td rowspan="1" colspan="1">3.343</td>
                        <td rowspan="1" colspan="1">82</td>
                        <td rowspan="1" colspan="1">2.751</td>
                        <td rowspan="1" colspan="1">100</td>
                        <td rowspan="1" colspan="1">4.061</td>
                        <td rowspan="1" colspan="1">
                          <p>1.48 (1.11–1.96)</p>
                        </td>
                      </tr>
                      <tr>
                        <td rowspan="2" colspan="1"/>
                        <td colspan="2" rowspan="1">Overall</td>
                        <td colspan="2" rowspan="1">
                          <p>Low-risk group</p>
                          <p>(CHA<sub>2</sub>DS<sub>2</sub>-VASc = 1–3)</p>
                        </td>
                        <td colspan="2" rowspan="1">
                          <p>High-risk group</p>
                          <p>(CHA<sub>2</sub>DS<sub>2</sub>-VASc ≥ 4)</p>
                        </td>
                        <td rowspan="2" colspan="1">
                          <p>RR (95% CI)<sup>a</sup></p>
                        </td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Number of patients</td>
                        <td rowspan="1" colspan="1">
                          <p>Incidence rate</p>
                          <p>(100 patient-years)</p>
                        </td>
                        <td rowspan="1" colspan="1">Number of patients</td>
                        <td rowspan="1" colspan="1">
                          <p>Incidence rate</p>
                          <p>(100 patient-years)</p>
                        </td>
                        <td rowspan="1" colspan="1">Number of patients</td>
                        <td rowspan="1" colspan="1">
                          <p>Incidence rate</p>
                          <p>(100 patient-years)</p>
                        </td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">AHRE ≤ 6 min</td>
                        <td rowspan="1" colspan="1">292</td>
                        <td rowspan="1" colspan="1">5.364</td>
                        <td rowspan="1" colspan="1">139</td>
                        <td rowspan="1" colspan="1">5.888</td>
                        <td rowspan="1" colspan="1">153</td>
                        <td rowspan="1" colspan="1">4.963</td>
                        <td rowspan="1" colspan="1">
                          <p>0.84 (0.68–1.05)</p>
                        </td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">6 min &lt; AHRE ≤ 6 h</td>
                        <td rowspan="1" colspan="1">653</td>
                        <td rowspan="1" colspan="1">11.995</td>
                        <td rowspan="1" colspan="1">258</td>
                        <td rowspan="1" colspan="1">10.929</td>
                        <td rowspan="1" colspan="1">395</td>
                        <td rowspan="1" colspan="1">12.812</td>
                        <td rowspan="1" colspan="1">
                          <p>1.17 (1.02–1.34)</p>
                        </td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">6 h &lt; AHRE ≤ 24 h</td>
                        <td rowspan="1" colspan="1">369</td>
                        <td rowspan="1" colspan="1">6.778</td>
                        <td rowspan="1" colspan="1">138</td>
                        <td rowspan="1" colspan="1">5.846</td>
                        <td rowspan="1" colspan="1">231</td>
                        <td rowspan="1" colspan="1">7.493</td>
                        <td rowspan="1" colspan="1">
                          <p>1.28 (1.05–1.56)</p>
                        </td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">AHRE &gt; 24 h</td>
                        <td rowspan="1" colspan="1">182</td>
                        <td rowspan="1" colspan="1">3.343</td>
                        <td rowspan="1" colspan="1">64</td>
                        <td rowspan="1" colspan="1">2.711</td>
                        <td rowspan="1" colspan="1">118</td>
                        <td rowspan="1" colspan="1">3.828</td>
                        <td rowspan="1" colspan="1">
                          <p>1.41 (1.05–1.90)</p>
                        </td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="tblfn4">
                      <p>AHRE, atrial high rate episode; CI, confidence interval; RR, risk ratio.</p>
                    </fn>
                    <fn id="tblfn5">
                      <label>a</label>
                      <p>Low-risk group as a reference.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>Similarly, we assessed this relationship using CHA<sub>2</sub>DS<sub>2</sub>-VASc score and observed the consistent results with the results using CHADS<sub>2</sub> score, showing significantly high incidence rates of AHRE &gt;6 h in high-risk patients (CHA<sub>2</sub>DS<sub>2</sub>-VASc score ≥4) compared to those at low risk (CHA<sub>2</sub>DS<sub>2</sub>-VASc score 1–3) (RR 1.282, 95% CI 1.053–1.560 for AHRE &gt;6 to ≤24 h, RR 1.412, 95% CI 1.052–1.896 for AHRE &gt;24 h). Furthermore, AHRE &gt;6 min to ≤6 h also occurred more frequently in high-risk patients compared to those at low risk (RR 1.172, 95% CI 1.022–1.345).</p>
                <p>In order to assess the relationship between the development of AHRE over time, we compared the follow-up duration among four AHRE categories. <italic toggle="yes">Table <xref rid="euab186-T1" ref-type="table">1</xref></italic> demonstrates that the follow-up duration in patients with AHRE &gt;24 h was significantly longer than those with AHRE &lt;6 min (<italic toggle="yes">P </italic>=<italic toggle="yes"> </italic>0.008), while there was no significant difference in the follow-up duration among other AHRE duration subgroups.</p>
              </sec>
              <sec>
                <title>Risk factors for the development of atrial high rate episode</title>
                <p>Cox regression analysis found heart failure inversely associated with the risk of AHRE ≤6 min [hazard ratio (HR) 0.58, 95% CI 0.40–0.85, <italic toggle="yes">P </italic>=<italic toggle="yes"> </italic>0.005]. Conversely, age ≥65 years and a history of AF or AFL were associated with AHRE of durations longer than 6 min (<italic toggle="yes">Figure <xref rid="euab186-F3" ref-type="fig">3A–</xref>D</italic>). Female gender was inversely associated with AHRE &gt;6 min to ≤6 h (HR 0.72, 95% CI 0.54–0.96, <italic toggle="yes">P </italic>=<italic toggle="yes"> </italic>0.027) and &gt;6 to ≤24 h (HR 0.70, 95% CI 0.49–1.02, <italic toggle="yes">P </italic>=<italic toggle="yes"> </italic>0.061). Hypertension was associated with AHRE &gt;24 h (HR 2.13, 95% CI 1.24–3.65, <italic toggle="yes">P </italic>=<italic toggle="yes"> </italic>0.006).</p>
                <fig position="float" id="euab186-F3">
                  <label>Figure 3</label>
                  <caption>
                    <p>Clinical factors associated with the development of each burden of AHRE [(<italic toggle="yes">A</italic>) AHRE &lt;6 min, (<italic toggle="yes">B</italic>) 6 min &lt; AHRE ≤ 6 h, (<italic toggle="yes">C</italic>) 6 h &lt; AHRE ≤ 24 h, and (<italic toggle="yes">D</italic>) AHRE &gt; 24 h]. ACE-I, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; AFL, atrial flutter; ARB, angiotensin II receptor blocker; CI, confidence interval; CM, cardiomyopathy; HR, hazard ratio; TIA, transient ischaemic attack.</p>
                  </caption>
                  <graphic xlink:href="euab186f3a" position="float"/>
                </fig>
                <fig position="float" id="euab186-F4">
                  <label>Figure 3d</label>
                  <graphic xlink:href="euab186f3b" position="float"/>
                </fig>
                <p>Additionally, we performed a subgroup analysis in patients without history of AF or AFL. In general, the consistent results of associations between AHRE and clinical factors were observed with the analysis for the entire population (<xref rid="sup1" ref-type="supplementary-material">Supplementary material</xref> online, <italic toggle="yes">Table</italic> <italic toggle="yes">S2</italic>). Several associations of long AHRE (&gt;24 h) with age ≥65 years and hypertension did not reach the statistically significant threshold in this analysis. This was in part due to a relative decrease in the number of patients with AHRE, although we found a trend for age ≥65 years and hypertension being associated with long AHRE (HR 1.44, 95% CI 0.99–2.09, <italic toggle="yes">P</italic> = 0.054 for age ≥65 years, HR 1.87, 95% CI 0.97–3.6, <italic toggle="yes">P</italic> = 0.063 for hypertension).</p>
              </sec>
              <sec>
                <title>Association of CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VASc scores with atrial high rate episode</title>
                <p>Receiver operating characteristic curves showed that the AUC values of the CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VASc scores for development of any burden of AHRE were low, ranging from 0.50 to 0.54, although there was a trend suggesting a relationship between the CHA<sub>2</sub>DS<sub>2</sub>-VASc score and AHRE &gt;24 h (AUC 0.54, 95% CI 0.50–0.58, <italic toggle="yes">P </italic>=<italic toggle="yes"> </italic>0.053; <xref rid="sup1" ref-type="supplementary-material">Supplementary material</xref> online, <italic toggle="yes">Table</italic> <italic toggle="yes">S3</italic>). There was no significant difference in AUC values between the CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VASc scores (<italic toggle="yes">P </italic>=<italic toggle="yes"> </italic>0.131 for AHRE ≤6 min, <italic toggle="yes">P </italic>=<italic toggle="yes"> </italic>0.679 for AHRE &gt;6 min to ≤6 h, <italic toggle="yes">P </italic>=<italic toggle="yes"> </italic>0.137 for AHRE &gt;6 to ≤24 h, and <italic toggle="yes">P </italic>=<italic toggle="yes"> </italic>0.768 for AHRE &gt;24 h).</p>
              </sec>
            </sec>
            <sec sec-type="discussion">
              <title>Discussion</title>
              <p>The main finding of this study is that in patients with ICD or CRT-D devices capable of continuous arrhythmia detection, specific patient characteristics are associated with the duration of atrial tachyarrhythmias. Older age and a history of AF or AFL were risk factors for AHRE of longer duration. Furthermore, hypertension showed a strong impact on the development of AHRE lasting &gt;24 h rather than age.</p>
              <p>In this population, AHRE between 6 min and 6 h was the most frequently detected duration. In previous studies, reported incidence rates of AHRE ranges from 30% to 70%,<xref rid="euab186-B5" ref-type="bibr"><sup>5</sup></xref> although incidence seems to depend on the clinical characteristics of each study population. An increased risk of adverse outcomes such as ischaemic stroke or systemic embolism has been associated with AHRE &gt;5–6 min.<xref rid="euab186-B4" ref-type="bibr"><sup>4</sup></xref> Whether AHRE have the same implications for antithrombotic prophylaxis as overt AF remains unclear.<xref rid="euab186-B14" ref-type="bibr"><sup>14</sup></xref> Cohort studies have demonstrated that stroke risk in untreated patients with AHRE increases with an increasing burden of AHRE,<xref rid="euab186-B15" ref-type="bibr"><sup>15</sup></xref> and the net benefit of anticoagulation therapy for patients with AHRE &gt;24 h is under investigation in clinical trials.<xref rid="euab186-B16" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="euab186-B17" ref-type="bibr"><sup>17</sup></xref> Anticoagulation may be considered for selected patients with longer burdens of AHRE (e.g. &gt;24 h), based upon anticipated clinical benefit, once patient preferences are also weighed. Clinical practice guidelines recommend careful monitoring of patients with device-detected AHRE, including remote monitoring systems, especially for patients with greater burdens of AHRE and high-risk clinical profiles.<xref rid="euab186-B10" ref-type="bibr"><sup>10</sup></xref></p>
              <p>Previous study demonstrated that patients who developed AHRE &gt;24 h showed a significantly higher risk of stroke or systemic embolism compared with those without AHRE, but other durations of AHRE did not show the association with an increased risk.<xref rid="euab186-B15" ref-type="bibr"><sup>15</sup></xref> In the present study, we found significant associations of AHRE &gt;24 h with age, history of AF or AFL, and hypertension. Among those risk factors, age was associated with AHRE &gt;24 h with a HR of 1.59, while hypertension showed more than two-hold risk for AHRE &gt;24 h. This result may suggest that blood pressure may be an important target as one of the modifiable clinical factors for the prevention from adverse outcomes such as stroke or systemic embolism in patients who develop AHRE. Furthermore, stratification of patients according to AHRE duration disclosed a sex-based difference, as women were less likely to exhibit AHRE from 6 min to 24 h duration. Despite a lower age-adjusted prevalence of overt AF in women compared with men, a difference in AHRE based on gender has not been previously reported and warrants confirmation in future studies. The association between use of digoxin and AHRE &gt;24 h is difficult to explain in the absence of data on serum digoxin dosage, plasma concentration, and indications for therapy. Indeed, at supra-therapeutic blood concentrations, digoxin is associated with an increased risk of adverse effects.<xref rid="euab186-B18" ref-type="bibr"><sup>18</sup></xref> We observed a negative association between short AHRE (&lt;6 min) and heart failure, but the clinical relevance of such short AHRE is not well established because AHRE lasting &lt;6 min was previously reported to have low positive predictive value for actual AF episodes.<xref rid="euab186-B19" ref-type="bibr"><sup>19</sup></xref> In addition, the LOOP (Atrial Fibrillation Detected by Continuous ECG Monitoring Using Implantable Loop Recorder to Prevent Stroke in High-risk Individuals) study showed that only a minority (16%) of short episodes of subclinical AF progressed to longer episodes &gt;24 h, and that 22% of patients with AF detected by implantable loop recorder had no other episodes of AF in a 3-year follow-up.<xref rid="euab186-B20" ref-type="bibr"><sup>20</sup></xref> Thus, we cautiously interpret the results regarding the associations between short AHRE and clinical characteristics.</p>
              <p>Use of the CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VASc scores has extended beyond assessment of thromboembolism risk to predict new-onset AF, left atrial remodelling, and AF recurrence after catheter ablation.<xref rid="euab186-B21" ref-type="bibr"><sup>21–23</sup></xref> We found no significant difference in the performance of the two scores to predict AHRE. In fact, unlike clinically manifest AF, these risk scores did not perform well in predicting device-detected AHRE of any duration. One explanation may be that AHRE relate more closely to arrhythmogenic atrial pathology than to thrombogenicity and risk of clinical ischaemic events.</p>
              <sec>
                <title>Limitations</title>
                <p>The present study has several limitations. First, the study population consisted of high-risk patients with ICD or CRT-D devices, who often had heart failure or other underlying heart disease associated with a risk of life-threatening arrhythmias. Their clinical characteristics may therefore differ from patients with other types of CIEDs, such as pacemakers and loop recorder. Although we investigated the relationship between clinical characteristics and the duration of AHRE, the association of AHRE with clinical outcomes, including stroke, heart failure, hospitalization, or mortality was not addressed because the IMPACT study randomly assigned patients to anticoagulation based on remote rhythm monitoring compared to conventional follow-up, which may affect the relationship between AHRE and clinical outcomes. Furthermore, we observed a significant difference in the follow-up durations between AHRE &lt;6 min and AHRE &gt;24 h, suggesting that long-term observation may more frequently detect longer AHRE duration during follow-up. Hence, the follow-up duration for each individual could possibly contribute to the results from this study, although there was no significant difference in the follow-up duration between other AHRE duration subgroups. Moreover, in the IMPACT study, AHREs were subjected to an adjudication by the expert committee in the case of events that would have triggered the initiation of anticoagulants. Although some of the AHREs might by chance be due to the false reading by CIEDs, longer AHREs were in general were subjected to an independent adjudication.</p>
              </sec>
            </sec>
            <sec>
              <title>Conclusions</title>
              <p>The duration of AHRE varies according to the clinical characteristics of patients with implanted defibrillator or resynchronization devices. Atrial high rate episode &gt;6 min to ≤6 h was most prevalent among all AHRE duration categories in patients with ICD or CRT-D. Longer AHREs more frequently occurred in patients at risk of thromboembolism. Age and history of AF/AFL were risk factors for AHRE &gt;6 min. Furthermore, hypertension showed a strong impact on the development of AHRE &gt;24 h rather than age.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary material</title>
              <p><xref rid="sup1" ref-type="supplementary-material">Supplementary material</xref> is available at <italic toggle="yes">Europace</italic> online.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <supplementary-material id="sup1" position="float" content-type="local-data">
                <label>euab186_Supplementary_Data</label>
                <media xlink:href="euab186_supplementary_data.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="ack1">
              <title>Acknowledgements</title>
              <p>The authors thank Crystal Miller, Eric Chenm, and Kazi Sharmin for contributions to data management, statistical analysis, and editing assistance for this study.</p>
            </ack>
            <sec>
              <title>Funding</title>
              <p>The IMPACT Study was supported by BIOTRONIK, Inc. (Lake Oswego, OR, USA).</p>
            </sec>
            <sec>
              <title> </title>
              <p><bold>Conflict of interest:</bold> G.Y.H.L. Consultant and speaker for BMS/Pfizer, Boehringer Ingelheim and Daiichi-Sankyo. No fees are received personally. D.T.M. is a consultant for Biotronik and Abbott. J.L.H. is a consultant for Biotronik, Abbott, and Medtronic. All other authors declared no conflict of interest.</p>
              <sec sec-type="data-availability">
                <title>Data availability</title>
                <p>The data underlying this article were provided by BIOTRONIK under licence. Data will be shared on request to the corresponding author with permission of BIOTRONIK.</p>
              </sec>
            </sec>
            <ref-list id="ref1">
              <title>References </title>
              <ref id="euab186-B1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vermond</surname><given-names>RA</given-names></string-name>, <string-name><surname>Geelhoed</surname><given-names>B</given-names></string-name>, <string-name><surname>Verweij</surname><given-names>N</given-names></string-name>, <string-name><surname>Tieleman</surname><given-names>RG</given-names></string-name>, <string-name><surname>Van der Harst</surname><given-names>P</given-names></string-name>, <string-name><surname>Hillege</surname><given-names>HL</given-names></string-name></person-group><etal>et al</etal><article-title>Incidence of atrial fibrillation and relationship with cardiovascular events, heart failure, and mortality: a community-based study from the Netherlands</article-title>. <source>J Am Coll Cardiol</source><year>2015</year>;<volume>66</volume>:<fpage>1000</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">26314526</pub-id></mixed-citation>
              </ref>
              <ref id="euab186-B2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gladstone</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Spring</surname><given-names>M</given-names></string-name>, <string-name><surname>Dorian</surname><given-names>P</given-names></string-name>, <string-name><surname>Panzov</surname><given-names>V</given-names></string-name>, <string-name><surname>Thorpe</surname><given-names>KE</given-names></string-name>, <string-name><surname>Hall</surname><given-names>J</given-names></string-name></person-group><etal>et al</etal><article-title>Atrial fibrillation in patients with cryptogenic stroke</article-title>. <source>N Engl J Med</source><year>2014</year>;<volume>370</volume>:<fpage>2467</fpage>–<lpage>77</lpage>.<pub-id pub-id-type="pmid">24963566</pub-id></mixed-citation>
              </ref>
              <ref id="euab186-B3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Grau</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Weimar</surname><given-names>C</given-names></string-name>, <string-name><surname>Buggle</surname><given-names>F</given-names></string-name>, <string-name><surname>Heinrich</surname><given-names>A</given-names></string-name>, <string-name><surname>Goertler</surname><given-names>M</given-names></string-name>, <string-name><surname>Neumaier</surname><given-names>S</given-names></string-name></person-group><etal>et al</etal><article-title>Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German Stroke Data Bank</article-title>. <source>Stroke</source><year>2001</year>;<volume>32</volume>:<fpage>2559</fpage>–<lpage>66</lpage>.<pub-id pub-id-type="pmid">11692017</pub-id></mixed-citation>
              </ref>
              <ref id="euab186-B4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Healey</surname><given-names>JS</given-names></string-name>, <string-name><surname>Connolly</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Gold</surname><given-names>MR</given-names></string-name>, <string-name><surname>Israel</surname><given-names>CW</given-names></string-name>, <string-name><surname>Van Gelder</surname><given-names>IC</given-names></string-name>, <string-name><surname>Capucci</surname><given-names>A</given-names></string-name></person-group><etal>et al</etal><article-title>Subclinical atrial fibrillation and the risk of stroke</article-title>. <source>N Engl J Med</source><year>2012</year>;<volume>366</volume>:<fpage>120</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">22236222</pub-id></mixed-citation>
              </ref>
              <ref id="euab186-B5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Freedman</surname><given-names>B</given-names></string-name>, <string-name><surname>Boriani</surname><given-names>G</given-names></string-name>, <string-name><surname>Glotzer</surname><given-names>TV</given-names></string-name>, <string-name><surname>Healey</surname><given-names>JS</given-names></string-name>, <string-name><surname>Kirchhof</surname><given-names>P</given-names></string-name>, <string-name><surname>Potpara</surname><given-names>TS.</given-names></string-name></person-group><article-title>Management of atrial high-rate episodes detected by cardiac implanted electronic devices</article-title>. <source>Nat Rev Cardiol</source><year>17</year>;<volume>14</volume>:<fpage>701</fpage>–<lpage>14</lpage>.<pub-id pub-id-type="pmid">28682320</pub-id></mixed-citation>
              </ref>
              <ref id="euab186-B6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Miyazawa</surname><given-names>K</given-names></string-name>, <string-name><surname>Pastori</surname><given-names>D</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y-G</given-names></string-name>, <string-name><surname>Székely</surname><given-names>O</given-names></string-name>, <string-name><surname>Shahid</surname><given-names>F</given-names></string-name>, <string-name><surname>Boriani</surname><given-names>G</given-names></string-name></person-group><etal>et al</etal><article-title>Atrial high rate episodes in patients with cardiac implantable electronic devices: implications for clinical outcomes</article-title>. <source>Clin Res Cardiol</source><year>2019</year>;<volume>108</volume>:<fpage>1034</fpage>–<lpage>41</lpage>.<pub-id pub-id-type="pmid">30759274</pub-id></mixed-citation>
              </ref>
              <ref id="euab186-B7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pastori</surname><given-names>D</given-names></string-name>, <string-name><surname>Miyazawa</surname><given-names>K</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name><surname>Székely</surname><given-names>O</given-names></string-name>, <string-name><surname>Shahid</surname><given-names>F</given-names></string-name>, <string-name><surname>Farcomeni</surname><given-names>A</given-names></string-name></person-group><etal>et al</etal><article-title>Atrial high-rate episodes and risk of major adverse cardiovascular events in patients with cardiac implantable electronic devices</article-title>. <source>Clin Res Cardiol</source><year>20</year>;<volume>109</volume>:<fpage>96</fpage>–<lpage>102</lpage>.<pub-id pub-id-type="pmid">31144064</pub-id></mixed-citation>
              </ref>
              <ref id="euab186-B8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gonzalez</surname><given-names>M</given-names></string-name>, <string-name><surname>Keating</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Markowitz</surname><given-names>SM</given-names></string-name>, <string-name><surname>Liu</surname><given-names>CF</given-names></string-name>, <string-name><surname>Thomas</surname><given-names>G</given-names></string-name>, <string-name><surname>Ip</surname><given-names>JE</given-names></string-name></person-group><etal>et al</etal><article-title>Newly detected atrial high rate episodes predict long-term mortality outcomes in patients with permanent pacemakers</article-title>. <source>Heart Rhythm</source><year>2014</year>;<volume>11</volume>:<fpage>2214</fpage>–<lpage>21</lpage>.<pub-id pub-id-type="pmid">25131667</pub-id></mixed-citation>
              </ref>
              <ref id="euab186-B9">
                <label>9</label>
                <mixed-citation publication-type="journal">Gorenek B, Bax J, Boriani G, Chen SA, Dagres N, Glotzer TV et al. Device-detected subclinical atrial tachyarrhythmias: definition, implications and management-an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrophysiology (SOLEACE). <italic toggle="yes">Europace</italic> 2017;19:1556-78.</mixed-citation>
              </ref>
              <ref id="euab186-B10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hindricks</surname><given-names>G</given-names></string-name>, <string-name><surname>Potpara</surname><given-names>T</given-names></string-name>, <string-name><surname>Dagres</surname><given-names>N</given-names></string-name>, <string-name><surname>Arbelo</surname><given-names>E</given-names></string-name>, <string-name><surname>Bax</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Blomström-Lundqvist</surname><given-names>C</given-names></string-name></person-group><etal>et al</etal>; ESC Scientific Document Group. <article-title>ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)</article-title>. <source>Eur Heart J</source><year>2021</year>;<volume>42</volume>:<fpage>373</fpage>–<lpage>498</lpage>.<pub-id pub-id-type="pmid">32860505</pub-id></mixed-citation>
              </ref>
              <ref id="euab186-B11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pastori</surname><given-names>D</given-names></string-name>, <string-name><surname>Miyazawa</surname><given-names>K</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name><surname>Shahid</surname><given-names>F</given-names></string-name>, <string-name><surname>Hado</surname><given-names>H</given-names></string-name>, <string-name><surname>Lip</surname><given-names>GYH.</given-names></string-name></person-group><article-title>Inflammation and the risk of atrial high-rate episodes (AHREs) in patients with cardiac implantable electronic devices</article-title>. <source>Clin Res Cardiol</source><year>2018</year>;<volume>107</volume>:<fpage>772</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">29667016</pub-id></mixed-citation>
              </ref>
              <ref id="euab186-B12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Martin</surname><given-names>DT</given-names></string-name>, <string-name><surname>Bersohn</surname><given-names>MM</given-names></string-name>, <string-name><surname>Waldo</surname><given-names>AL</given-names></string-name>, <string-name><surname>Wathen</surname><given-names>MS</given-names></string-name>, <string-name><surname>Choucair</surname><given-names>WK</given-names></string-name>, <string-name><surname>Lip</surname><given-names>GYH</given-names></string-name></person-group><etal>et al</etal><article-title>Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices</article-title>. <source>Eur Heart J</source><year>2015</year>;<volume>36</volume>:<fpage>1660</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">25908774</pub-id></mixed-citation>
              </ref>
              <ref id="euab186-B13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>DeLong</surname><given-names>ER</given-names></string-name>, <string-name><surname>DeLong</surname><given-names>DM</given-names></string-name>, <string-name><surname>Clarke-Pearson</surname><given-names>DL.</given-names></string-name></person-group><article-title>Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach</article-title>. <source>Biometrics</source><year>88</year>;<volume>44</volume>:<fpage>837</fpage>–<lpage>45</lpage>.<pub-id pub-id-type="pmid">3203132</pub-id></mixed-citation>
              </ref>
              <ref id="euab186-B14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bertaglia</surname><given-names>E</given-names></string-name>, <string-name><surname>Blank</surname><given-names>B</given-names></string-name>, <string-name><surname>Blomström-Lundqvist</surname><given-names>C</given-names></string-name>, <string-name><surname>Brandes</surname><given-names>A</given-names></string-name>, <string-name><surname>Cabanelas</surname><given-names>N</given-names></string-name>, <string-name><surname>Dan</surname><given-names>G-A</given-names></string-name></person-group><etal>et al</etal><article-title>Atrial high-rate episodes: prevalence, stroke risk, implications for management, and clinical gaps in evidence</article-title>. <source>Europace</source><year>2019</year>;<volume>21</volume>:<fpage>1459</fpage>–<lpage>67</lpage>.<pub-id pub-id-type="pmid">31377792</pub-id></mixed-citation>
              </ref>
              <ref id="euab186-B15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Van Gelder</surname><given-names>IC</given-names></string-name>, <string-name><surname>Healey</surname><given-names>JS</given-names></string-name>, <string-name><surname>Crijns</surname><given-names>HJGM</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name><surname>Hohnloser</surname><given-names>SH</given-names></string-name>, <string-name><surname>Gold</surname><given-names>MR</given-names></string-name></person-group><etal>et al</etal><article-title>Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT</article-title>. <source>Eur Heart J</source><year>17</year>;<volume>38</volume>:<fpage>1339</fpage>–<lpage>44</lpage>.<pub-id pub-id-type="pmid">28329139</pub-id></mixed-citation>
              </ref>
              <ref id="euab186-B16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lopes</surname><given-names>RD</given-names></string-name>, <string-name><surname>Alings</surname><given-names>M</given-names></string-name>, <string-name><surname>Connolly</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Beresh</surname><given-names>H</given-names></string-name>, <string-name><surname>Granger</surname><given-names>CB</given-names></string-name>, <string-name><surname>Mazuecos</surname><given-names>JB</given-names></string-name></person-group><etal>et al</etal><article-title>Rationale and design of the apixaban for the reduction of thrombo-embolism in patients with device-detected sub-clinical atrial fibrillation (ARTESiA) trial</article-title>. <source>Am Heart J</source><year>2017</year>;<volume>189</volume>:<fpage>137</fpage>–<lpage>45</lpage>.<pub-id pub-id-type="pmid">28625370</pub-id></mixed-citation>
              </ref>
              <ref id="euab186-B17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kirchhof</surname><given-names>P</given-names></string-name>, <string-name><surname>Blank</surname><given-names>BF</given-names></string-name>, <string-name><surname>Calvert</surname><given-names>M</given-names></string-name>, <string-name><surname>Camm</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Chlouverakis</surname><given-names>G</given-names></string-name>, <string-name><surname>Diener</surname><given-names>H-C</given-names></string-name></person-group><etal>et al</etal><article-title>Probing oral anticoagulation in patients with atrial high rate episodes: rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial</article-title>. <source>Am Heart J</source><year>2017</year>;<volume>190</volume>:<fpage>12</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">28760205</pub-id></mixed-citation>
              </ref>
              <ref id="euab186-B18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pastori</surname><given-names>D</given-names></string-name>, <string-name><surname>Carnevale</surname><given-names>R</given-names></string-name>, <string-name><surname>Nocella</surname><given-names>C</given-names></string-name></person-group><etal>et al</etal><article-title>Digoxin and platelet activation in patients with atrial fibrillation: in vivo and in vitro study</article-title>. <source>J Am Heart Assoc</source><year>2018</year>;<volume>7</volume>:<fpage>e009509</fpage>.<pub-id pub-id-type="pmid">30571484</pub-id></mixed-citation>
              </ref>
              <ref id="euab186-B19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kaufman</surname><given-names>ES</given-names></string-name>, <string-name><surname>Israel</surname><given-names>CW</given-names></string-name>, <string-name><surname>Nair</surname><given-names>GM</given-names></string-name>, <string-name><surname>Armaganijan</surname><given-names>L</given-names></string-name>, <string-name><surname>Divakaramenon</surname><given-names>S</given-names></string-name>, <string-name><surname>Mairesse</surname><given-names>GH</given-names></string-name></person-group><etal>et al</etal>; ASSERT Steering Committee and Investigators. <article-title>Positive predictive value of device-detected atrial high-rate episodes at different rates and durations: an analysis from ASSERT</article-title>. <source>Heart Rhythm</source><year>12</year>;<volume>9</volume>:<fpage>1241</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">22440154</pub-id></mixed-citation>
              </ref>
              <ref id="euab186-B20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Diederichsen</surname><given-names>SZ</given-names></string-name>, <string-name><surname>Haugan</surname><given-names>KJ</given-names></string-name>, <string-name><surname>Brandes</surname><given-names>A</given-names></string-name>, <string-name><surname>Lanng</surname><given-names>MB</given-names></string-name>, <string-name><surname>Graff</surname><given-names>C</given-names></string-name>, <string-name><surname>Krieger</surname><given-names>D</given-names></string-name></person-group><etal>et al</etal><article-title>Natural history of subclinical atrial fibrillation detected by implanted loop recorders</article-title>. <source>J Am Coll Cardiol</source><year>2019</year>;<volume>74</volume>:<fpage>2771</fpage>–<lpage>81</lpage>.<pub-id pub-id-type="pmid">31779791</pub-id></mixed-citation>
              </ref>
              <ref id="euab186-B21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chao</surname><given-names>T-F</given-names></string-name>, <string-name><surname>Lin</surname><given-names>Y-J</given-names></string-name>, <string-name><surname>Tsao</surname><given-names>H-M</given-names></string-name>, <string-name><surname>Tsai</surname><given-names>C-F</given-names></string-name>, <string-name><surname>Lin</surname><given-names>W-S</given-names></string-name>, <string-name><surname>Chang</surname><given-names>S-L</given-names></string-name></person-group><etal>et al</etal><article-title>CHADS(2) and CHA(2)DS(2)-VASc scores in the prediction of clinical outcomes in patients with atrial fibrillation after catheter ablation</article-title>. <source>J Am Coll Cardiol</source><year>2011</year>;<volume>58</volume>:<fpage>2380</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">22115643</pub-id></mixed-citation>
              </ref>
              <ref id="euab186-B22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name><surname>Ding</surname><given-names>W</given-names></string-name>, <string-name><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name><surname>Song</surname><given-names>N</given-names></string-name>, <string-name><surname>Lin</surname><given-names>L</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Z</given-names></string-name></person-group><etal>et al</etal><article-title>Relationship of CHA2DS2-VASc and CHADS2 score to left atrial remodeling detected by velocity vector imaging in patients with atrial fibrillation</article-title>. <source>PLoS One</source><year>2013</year>;<volume>8</volume>:<fpage>e77653</fpage>.<pub-id pub-id-type="pmid">24147047</pub-id></mixed-citation>
              </ref>
              <ref id="euab186-B23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Saliba</surname><given-names>W</given-names></string-name>, <string-name><surname>Gronich</surname><given-names>N</given-names></string-name>, <string-name><surname>Barnett-Griness</surname><given-names>O</given-names></string-name>, <string-name><surname>Rennert</surname><given-names>G.</given-names></string-name></person-group><article-title>Usefulness of CHADS2 and CHA2DS2-VASc scores in the prediction of new-onset atrial fibrillation: a population-based study</article-title>. <source>Am J Med</source><year>2016</year>;<volume>129</volume>:<fpage>843</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">27012854</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
